a 2022

Plasma levels of immune checkpoint inhibitor ligands PD-L1, B7-H3 and galectin-9 in glioblastoma patients

TOMANDLOVÁ, Marie, Martin PISKÁČEK, Vilém JURÁŇ, Marek SOVA, Martin SMRČKA et. al.

Basic information

Original name

Plasma levels of immune checkpoint inhibitor ligands PD-L1, B7-H3 and galectin-9 in glioblastoma patients

Authors

TOMANDLOVÁ, Marie (203 Czech Republic, belonging to the institution), Martin PISKÁČEK (40 Austria, belonging to the institution), Vilém JURÁŇ (203 Czech Republic, belonging to the institution), Marek SOVA (203 Czech Republic, belonging to the institution), Martin SMRČKA (203 Czech Republic, belonging to the institution), Václav VYBÍHAL (203 Czech Republic, belonging to the institution), Pavel FADRUS (203 Czech Republic, belonging to the institution), Tomáš KAZDA (203 Czech Republic, belonging to the institution) and Andrea KNIGHT (203 Czech Republic, guarantor, belonging to the institution)

Edition

Brain Tumour Conference 2022, 5-7 September 2022, London, 2022

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30102 Immunology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/22:00129682

Organization unit

Faculty of Medicine

Keywords in English

PD-L1; B7-H3; galectin-9; plasma levels; glioblastoma

Tags

Tags

International impact
Změněno: 4/5/2023 08:21, Mgr. Tereza Miškechová

Abstract

V originále

Plasma levels of immune checkpoint inhibitor ligands PD-L1, B7-H3 and galectin-9 in glioblastoma patients - conference abstract.

Links

NV19-05-00410, research and development project
Name: Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme
Investor: Ministry of Health of the CR